Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission. Printed by #UserName#, #Company_Name#


Printed By

UsernamePublicRestriction

'Increased cost' for pharmacies under pregabalin controlled drug plans

Community pharmacies might be hit with extra storage costs if government plans to reclassify pregabalin and gabapentin as controlled drugs are approved.

The 10-week Home Office consultation – which launched on Monday (November 13) – proposes three options for the reclassification of the two drugs.

The first – and "preferred option" – is placing the drugs in schedule 3 under the Misuse of Drugs Regulations 2001 and requiring them to be stored in safes.

If the government selects this option, "some organisations such as community pharmacies" may face the "increased costs" of acquiring additional safes to store the drugs in, according to the Home Office's impact assessment.

"[This option] would provide the largest benefit to society to prevent the two drugs being diverted into the illicit market, owing to the requirement to store the drugs in safes," the Home Office said.

"However, some organisations – such as community pharmacies – may struggle to store the two drugs in their existing safes and may need to acquire additional safes if the safe custody provisions apply."

The other two options for reclassification are: for pregabalin and gabapentin to be placed under schedule 3 without the need to be stored in safes; or to be placed under schedule 4 part 1 – alongside drugs such as lorazepam and diazepam.

Reclassifying the two drugs and storing them in safes was recommended by the Advisory Council on the Misuse of Drugs (ACMD) in January 2016, the Home Office pointed out.

At the time, the ACMD suggested that pregabalin and gabapentin should become class C drugs, noting that their "risk of addiction, potential illegal diversion and medicinal misuse" are equivalent to existing class C drugs such as tramadol.

Pharmacists have until January 22, 2018 to submit their responses to the consultation via an online questionnaire.

What impact would the reclassification of pregabalin and gabapentin have in your pharmacy?

Related Content

Topics

Pre-reg Trainee

Tonbridge, Kent

 Salary: £22,000

Apply Now
UsernamePublicRestriction

Register

CD009047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel